HC Wainwright Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)
HC Wainwright reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $95.00 price target on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.63) EPS, […]
More Stories
Envestnet Portfolio Solutions Inc. Has $3.89 Million Position in Citigroup Inc. (NYSE:C)
Envestnet Portfolio Solutions Inc. cut its holdings in Citigroup Inc. (NYSE:C – Free Report) by 26.1% in the 1st quarter,...
Schwab US Large-Cap ETF (NYSEARCA:SCHX) Shares Sold by Kingswood Wealth Advisors LLC
Kingswood Wealth Advisors LLC cut its holdings in shares of Schwab US Large-Cap ETF (NYSEARCA:SCHX – Free Report) by 22.2%...
Blue Trust Inc. Raises Stock Holdings in Boston Scientific Corporation (NYSE:BSX)
Blue Trust Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 13.0% during the...
Johnson Investment Counsel Inc. Has $936,000 Holdings in Welltower Inc. (NYSE:WELL)
Johnson Investment Counsel Inc. lessened its stake in Welltower Inc. (NYSE:WELL – Free Report) by 15.9% in the 1st quarter,...
Blue Trust Inc. Buys 434 Shares of General Dynamics Corporation (NYSE:GD)
Blue Trust Inc. increased its position in shares of General Dynamics Corporation (NYSE:GD – Free Report) by 26.8% during the...
CWA Asset Management Group LLC Acquires Shares of 1,716 Yum! Brands, Inc. (NYSE:YUM)
CWA Asset Management Group LLC purchased a new position in Yum! Brands, Inc. (NYSE:YUM – Free Report) during the 1st...